vs
Side-by-side financial comparison of NACCO INDUSTRIES INC (NC) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Vericel Corp is the larger business by last-quarter revenue ($92.9M vs $62.8M, roughly 1.5× NACCO INDUSTRIES INC). Vericel Corp runs the higher net margin — 25.0% vs 14.1%, a 10.9% gap on every dollar of revenue. On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs -4.3%). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 9.5%).
NACCO Industries, Inc. is an American publicly traded holding company, headquartered in Cleveland, Ohio. Through a portfolio of mining and natural resources businesses, the company operates under three business segments: Coal Mining, North American Mining, and Minerals Management. The Coal Mining segment operates surface coal mines under long-term contracts with power generation companies and an activated carbon producer pursuant to a service-based business model. The North American Mining se...
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
NC vs VCEL — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $62.8M | $92.9M |
| Net Profit | $8.8M | $23.2M |
| Gross Margin | 22.8% | 78.7% |
| Operating Margin | 17.5% | 24.1% |
| Net Margin | 14.1% | 25.0% |
| Revenue YoY | -4.3% | 23.3% |
| Net Profit YoY | 80.0% | 17.3% |
| EPS (diluted) | $1.17 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $62.8M | — | ||
| Q4 25 | $66.8M | $92.9M | ||
| Q3 25 | $76.6M | $67.5M | ||
| Q2 25 | $68.2M | $63.2M | ||
| Q1 25 | $65.6M | $52.6M | ||
| Q4 24 | $70.4M | $75.4M | ||
| Q3 24 | $61.7M | $57.9M | ||
| Q2 24 | $52.3M | $52.7M |
| Q1 26 | $8.8M | — | ||
| Q4 25 | $-3.8M | $23.2M | ||
| Q3 25 | $13.3M | $5.1M | ||
| Q2 25 | $3.3M | $-553.0K | ||
| Q1 25 | $4.9M | $-11.2M | ||
| Q4 24 | $7.6M | $19.8M | ||
| Q3 24 | $15.6M | $-901.0K | ||
| Q2 24 | $6.0M | $-4.7M |
| Q1 26 | 22.8% | — | ||
| Q4 25 | 18.0% | 78.7% | ||
| Q3 25 | 13.0% | 73.5% | ||
| Q2 25 | 10.0% | 73.7% | ||
| Q1 25 | 14.7% | 69.0% | ||
| Q4 24 | 12.0% | 77.6% | ||
| Q3 24 | 11.7% | 71.9% | ||
| Q2 24 | 13.4% | 69.5% |
| Q1 26 | 17.5% | — | ||
| Q4 25 | 11.3% | 24.1% | ||
| Q3 25 | 8.8% | 5.1% | ||
| Q2 25 | -0.1% | -3.2% | ||
| Q1 25 | 11.7% | -24.3% | ||
| Q4 24 | 5.5% | 24.5% | ||
| Q3 24 | 31.9% | -4.3% | ||
| Q2 24 | 14.1% | -11.5% |
| Q1 26 | 14.1% | — | ||
| Q4 25 | -5.8% | 25.0% | ||
| Q3 25 | 17.3% | 7.5% | ||
| Q2 25 | 4.8% | -0.9% | ||
| Q1 25 | 7.5% | -21.4% | ||
| Q4 24 | 10.7% | 26.3% | ||
| Q3 24 | 25.4% | -1.6% | ||
| Q2 24 | 11.4% | -8.9% |
| Q1 26 | $1.17 | — | ||
| Q4 25 | $-0.53 | $0.46 | ||
| Q3 25 | $1.78 | $0.10 | ||
| Q2 25 | $0.44 | $-0.01 | ||
| Q1 25 | $0.66 | $-0.23 | ||
| Q4 24 | $0.99 | $0.40 | ||
| Q3 24 | $2.14 | $-0.02 | ||
| Q2 24 | $0.81 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $354.6M |
| Total Assets | — | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $49.7M | $137.5M | ||
| Q3 25 | $52.7M | $135.4M | ||
| Q2 25 | $49.4M | $116.9M | ||
| Q1 25 | $61.9M | $112.9M | ||
| Q4 24 | $72.8M | $116.2M | ||
| Q3 24 | $63.1M | $101.7M | ||
| Q2 24 | $62.4M | $102.5M |
| Q1 26 | — | — | ||
| Q4 25 | $100.8M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $99.4M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $29.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | $429.2M | $354.6M | ||
| Q3 25 | $426.4M | $321.9M | ||
| Q2 25 | $413.1M | $306.8M | ||
| Q1 25 | $409.1M | $295.5M | ||
| Q4 24 | $404.9M | $292.0M | ||
| Q3 24 | $397.3M | $257.5M | ||
| Q2 24 | $384.1M | $243.0M |
| Q1 26 | — | — | ||
| Q4 25 | $661.2M | $488.0M | ||
| Q3 25 | $637.6M | $453.3M | ||
| Q2 25 | $631.3M | $435.6M | ||
| Q1 25 | $634.2M | $424.6M | ||
| Q4 24 | $631.7M | $432.7M | ||
| Q3 24 | $597.4M | $390.4M | ||
| Q2 24 | $560.1M | $376.8M |
| Q1 26 | — | — | ||
| Q4 25 | 0.23× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.25× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.08× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $15.0M |
| Free Cash FlowOCF − Capex | — | $12.8M |
| FCF MarginFCF / Revenue | — | 13.8% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | — | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | — | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $11.4M | $15.0M | ||
| Q3 25 | $42.3M | $22.1M | ||
| Q2 25 | $-7.8M | $8.2M | ||
| Q1 25 | $5.0M | $6.6M | ||
| Q4 24 | $25.2M | $22.2M | ||
| Q3 24 | $2.8M | $10.2M | ||
| Q2 24 | $4.1M | $18.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | $12.8M | ||
| Q3 25 | — | $19.5M | ||
| Q2 25 | — | $81.0K | ||
| Q1 25 | — | $-7.6M | ||
| Q4 24 | — | $8.5M | ||
| Q3 24 | — | $-9.2M | ||
| Q2 24 | — | $1.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | 13.8% | ||
| Q3 25 | — | 28.8% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | -14.5% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | — | -15.9% | ||
| Q2 24 | — | 3.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.4% | ||
| Q3 25 | — | 3.9% | ||
| Q2 25 | — | 12.9% | ||
| Q1 25 | — | 27.0% | ||
| Q4 24 | — | 18.3% | ||
| Q3 24 | — | 33.5% | ||
| Q2 24 | — | 31.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.65× | ||
| Q3 25 | 3.19× | 4.35× | ||
| Q2 25 | -2.39× | — | ||
| Q1 25 | 1.03× | — | ||
| Q4 24 | 3.33× | 1.12× | ||
| Q3 24 | 0.18× | — | ||
| Q2 24 | 0.68× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NC
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
